Insulin degludec/insulin aspart

Insulin degludec/insulin aspart, sold under the brand name Ryzodeg, is a fixed-dose combination medication for the treatment of diabetes mellitus.[4] It contains insulin degludec and insulin aspart.[4] It is given as an injection under the skin in the abdominal wall (at the front of the waist), upper arm or thigh.[4]

Insulin degludec/insulin aspart
Combination of
Insulin degludecLong-acting human insulin analog
Insulin aspartFast-acting human insulin analog
Clinical data
Trade namesRyzodeg
AHFS/Drugs.comProfessional Drug Facts
License data
Pregnancy
category
    Routes of
    administration    		Subcutaneous injection
    ATC code
    Legal status
    Legal status
    Identifiers
    KEGG

    The most frequently reported side effect is hypoglycemia (low blood glucose levels).[4]

    It was approved for medical use in the European Union in January 2013,[4] and in Australia in November 2017.[2][3]

    Medical uses

    Insulin degludec/insulin aspart is indicated for the treatment of diabetes mellitus in adults, adolescents and children from the age of two years.[4]

    Insulin degludec and insulin aspart are slightly different from human insulin.[4] The differences mean that insulin degludec is absorbed more slowly by the body.[4] This means it has a long duration of action.[4] Meanwhile, insulin aspart is absorbed faster by the body than human insulin, and therefore it starts to work as soon as it is injected and has a short duration of action.[4]

    gollark: Personally, such drugs seem annoying to get, and I don't really see the attraction, so meh.
    gollark: I'm not sure I've actually ever heard anyone use that acronym in any case.
    gollark: Nope.
    gollark: This inspired me to look at the server's search results for LSD, and there are surprisingly many of them?
    gollark: Lasers are of course very dangerous drugs.

    References
    1. "Insulin aspart / insulin degludec (Ryzodeg 70/30) Use During Pregnancy". Drugs.com. 30 June 2020. Retrieved 26 July 2020.
    2. "Ryzodeg ARTG ID 280432". Therapeutic Goods Administration (TGA). Retrieved 21 July 2020.
    3. "Ryzodeg ARTG ID 280433". Therapeutic Goods Administration (TGA). Retrieved 21 July 2020.
    4. "Ryzodeg EPAR". European Medicines Agency (EMA). Retrieved 18 July 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.


    This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.